Roche Acquires PathAI For $1.05 Billion
Swiss pharmaceutical group Roche has agreed to acquire US-based AI diagnostic tool maker PathAI. The deal is valued at up to $1.05 billion, including $750 million in upfront payment, with a projected close in the second half of 2026. No new details provided in current feeds.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Mastodon
“Swiss pharmaceutical group Roche agrees to acquire US-based PathAI, which makes AI diagnostic tools, for up to $1.05B, with $750M upfront, closing in H2 2026”
CRI Huayu Global
“罗氏以10.5亿美元收购了PathAI。”
CRI Huayu Global
“罗氏公司以10.5亿美元收购了PathAI公司。”
CRI Huayu Global
“罗氏公司以10.5亿美元的价格收购了PathAI公司。”
RTHK Radio 1 Cantonese
“Roche has acquired PathAI for $1.05 billion.”
CRI Huayu Global
“Roche Acquires PathAI For $1.05 Billion”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade